This guide explains how dietary supplement compliance matters work for businesses in Miami — the rules, the deadlines, the process and the mistakes — and how Garg Law handles them. Miami is the principal port of entry for the southeastern United States — PortMiami and Miami International Airport together move a huge share of the country’s waterborne and air cargo, and the businesses that import, distribute and market FDA-regulated products across the Americas run their operations from here. More FDA-regulated freight crosses this city than almost any other American market.
Quick answer
Supplements live under DSHEA’s bargain: no pre-approval, but strict rules on ingredients, claims, manufacturing and labeling — and aggressive FDA enforcement at the border and in the market when brands overstep. Compliance work means keeping ingredients lawful, claims substantiated and cGMP records inspection-ready.
1. Overview: the regulatory framework
The Dietary Supplement Health and Education Act (DSHEA) lets supplements reach market without pre-approval, but the conditions are real: ingredients must be lawful dietary ingredients — with new dietary ingredient (NDI) notifications for those not marketed before 1994 — manufacturing must meet the cGMP rule at 21 CFR Part 111, and labels must carry the Supplement Facts panel and required disclaimers.
Claims are the classic trap. Structure/function claims (“supports immune health”) are permitted with substantiation, notification to FDA and the DSHEA disclaimer; disease claims (“treats,” “cures,” “prevents”) convert the product into an unapproved drug instantly — a favorite basis for warning letters, import refusals and injunctions. Website copy, social media and influencer posts all count as labeling.
Importers face a second front: supplement ingredients and finished products are heavily screened, several appear on import alerts, and FDA detains shipments over unlisted facilities, adulteration concerns and drug claims on labels. Adverse event reporting obligations for serious events round out the regime.
2. What is at stake
Supplements draw disproportionate FDA and FTC attention — disease-claim warning letters arrive in waves, import alerts cover whole ingredient classes, and cGMP inspection failures halt production. For brands built on a hero ingredient, one adverse regulatory finding can take the flagship product off the market.
3. Step-by-step: how the matter proceeds
- Ingredient review: dietary-ingredient status, NDI analysis, and the additive/GRAS questions for combination products
- Claims audit across labels, websites and marketing — substantiation files and disease-claim scrubbing
- cGMP program review against 21 CFR Part 111: specifications, testing, batch records, qualified personnel
- Import strategy for ingredients and finished goods — entry data, supplier documentation, alert management
- Enforcement response: 483s, warning letters, detentions and the corrective packages that resolve them
4. Common errors to avoid
- Letting marketing write disease claims the regulatory file cannot support
- Launching an ingredient that needed an NDI notification nobody filed
- Relying on a contract manufacturer’s cGMP without your own specifications and oversight — the brand owns compliance too
- Ignoring what the website and social accounts say, as if only the bottle were the label
- Importing ingredients from suppliers already on import alert
Miami: the local picture
The work around Miami — international trade companies, food and beverage importers, cosmetics and consumer brands, medical and pharmaceutical distributors, logistics and freight networks — is FDA-regulated at nearly every turn, and matters here move on the gateway city — PortMiami, Miami International Airport and the headquarters of hemispheric trade. Garg Law's Miami office is at 1221 Brickell Avenue, and the practice was built for exactly this market: founder Shelly Garg spent years counseling importers at the world's largest dedicated international trade law firm before opening her own, and works at the crossroads of FDA and CBP compliance for foreign and domestic companies across the food, beverage, supplement, cosmetics, OTC drug and medical device industries.
Frequently asked questions
Do dietary supplements need FDA approval?
No pre-market approval — but that is not deregulation. Ingredients must qualify as dietary ingredients (with NDI notifications where required), manufacturing must meet Part 111 cGMPs, labels must be compliant, and claims must stay on the structure/function side of the line. FDA enforces all of it after market entry and at the border.
What claims can a supplement legally make?
Structure/function claims about normal body function, with substantiation, a 30-day notification to FDA and the DSHEA disclaimer. Claims to diagnose, treat, cure or prevent disease are drug claims — the fastest route to a warning letter or an import refusal that exists in this industry.
What is an NDI notification and do I need one?
A new dietary ingredient — one not marketed in the U.S. before October 15, 1994 — generally requires a safety notification to FDA 75 days before marketing. Skipping it renders the product adulterated. Whether your ingredient needs one is a factual and legal analysis worth doing before launch, not after a warning letter.
Why was my supplement shipment detained at the port?
Common bases: labels bearing disease claims, unregistered or unverifiable facilities, ingredients on import alert, or adulteration concerns. Supplement entries through Miami are screened hard; the response depends on the specific charge on the Notice of FDA Action.
Does FDA inspect supplement brands or just manufacturers?
Both. Own-label distributors are held to Part 111 obligations they often do not realize they carry — specifications, supplier qualification, complaint files and adverse event records. A brand that cannot produce those records fails an inspection regardless of how good its co-packer is.